Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
AssigneeShanghai Regenelead Therapies Co., Ltd.
InventorsJun Jiang, Mingyue Wu, Wei Ning, Cheng Liao
Life of this patent
Estimating the term…
Abstract
Provided are an aromatic L-amino acid decarboxylase (AADC)/glial cell line-derived neurotrophic factor (GDNF) polynucleotide, and a use thereof in treating Parkinson's disease. Specifically, provided are a method for and a use in treating neurodegenerative diseases (such as Parkinson's disease) by delivering AADC and a GDNF to specific areas of the brain by a gene delivery system using AAV as a vector.
Claims27
A nucleic acid molecule, comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes aromatic L-amino acid decarboxylase (AADC) protein, and the second polynucleotide encodes glial cell line-derived neurotrophic factor (GDNF) protein.
(canceled)
A nucleic acid molecule, wherein the nucleic acid molecule comprises
- a polynucleotide encoding AADC protein, wherein the nucleic acid molecule comprises the sequence set forth in any one of SEQ ID NOs:
- 4-7 or a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 4-7;
- or,
- a polynucleotide encoding GDNF protein, wherein the nucleic acid molecule comprises the sequence set forth in any one of SEQ ID NOs:
- 9-12 or a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 9-12.
(canceled)
(canceled)
Dependencies are inferred from the claim text.